Latent cytomegalovirus down-regulates major histocompatibility complex class II expression on myeloid progenitors.

A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection. J Virol (2004) 1.57

Experimental human cytomegalovirus latency in CD14+ monocytes. Proc Natl Acad Sci U S A (2010) 1.26

Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection. J Virol (2008) 1.22

Human cytomegalovirus interleukin-10 polarizes monocytes toward a deactivated M2c phenotype to repress host immune responses. J Virol (2013) 0.98

Impact of human cytomegalovirus latent infection on myeloid progenitor cell gene expression. J Virol (2004) 0.97

Chromatin-mediated regulation of cytomegalovirus gene expression. Virus Res (2010) 0.97

Circulating dendritic cells isolated from healthy seropositive donors are sites of human cytomegalovirus reactivation in vivo. J Virol (2013) 0.91

Cytomegalovirus immune evasion by perturbation of endosomal trafficking. Cell Mol Immunol (2014) 0.89

Regulation of human cytomegalovirus transcription in latency: beyond the major immediate-early promoter. Viruses (2013) 0.83

Human cytomegalovirus manipulation of latently infected cells. Viruses (2013) 0.81

Incidence of Ganciclovir Resistance in CMV-positive Renal Transplant Recipients and its Association with UL97 Gene Mutations. Iran J Pharm Res (2017) 0.75

Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science (2002) 7.70

RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature (2011) 6.03

Virus inhibition of RIP3-dependent necrosis. Cell Host Microbe (2010) 3.70

DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe (2012) 3.23

Activation of innate immunity is required for efficient nuclear reprogramming. Cell (2012) 2.99

Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol (2006) 2.97

Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One (2008) 2.83

NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med (2003) 2.75

Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med (2002) 2.73

Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol (2006) 2.67

Retracted CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med (2013) 2.51

Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis (2008) 2.37

Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem (2013) 2.24

Disruption of mitochondrial networks by the human cytomegalovirus UL37 gene product viral mitochondrion-localized inhibitor of apoptosis. J Virol (2003) 2.03

Pathogen subversion of cell-intrinsic innate immunity. Nat Immunol (2007) 1.97

Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J Virol (2004) 1.94

Varicella-zoster virus infection of human dorsal root ganglia in vivo. Proc Natl Acad Sci U S A (2005) 1.89

Construction of varicella-zoster virus recombinants from parent Oka cosmids and demonstration that ORF65 protein is dispensable for infection of human skin and T cells in the SCID-hu mouse model. J Virol (2003) 1.86

Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med (2004) 1.85

Cytomegalovirus M45 cell death suppression requires receptor-interacting protein (RIP) homotypic interaction motif (RHIM)-dependent interaction with RIP1. J Biol Chem (2008) 1.78

A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9. J Virol (2007) 1.76

Differential function and expression of the viral inhibitor of caspase 8-induced apoptosis (vICA) and the viral mitochondria-localized inhibitor of apoptosis (vMIA) cell death suppressors conserved in primate and rodent cytomegaloviruses. Virology (2003) 1.75

Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression. Immunol Rev (2005) 1.74

Cutting edge: FAS (CD95) mediates noncanonical IL-1β and IL-18 maturation via caspase-8 in an RIP3-independent manner. J Immunol (2012) 1.71

Receptor-interacting protein homotypic interaction motif-dependent control of NF-kappa B activation via the DNA-dependent activator of IFN regulatory factors. J Immunol (2008) 1.66

Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation (2004) 1.62

Precarious balance: Th17 cells in host defense. Infect Immun (2009) 1.60

A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection. J Virol (2004) 1.57

Chaperone activity of α B-crystallin is responsible for its incorrect assignment as an autoantigen in multiple sclerosis. J Immunol (2011) 1.56

T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. J Clin Invest (2004) 1.56

Varicella-zoster virus ORF63 inhibits apoptosis of primary human neurons. J Virol (2006) 1.54

Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J Virol (2002) 1.53

T cell-mediated autoimmune disease due to low-affinity crossreactivity to common microbial peptides. Immunity (2009) 1.50

Virus-encoded homologs of cellular interleukin-10 and their control of host immune function. J Virol (2009) 1.49

Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol (2005) 1.48

T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation (2006) 1.46

Maternal herpes simplex virus antibody avidity and risk of neonatal herpes. Am J Obstet Gynecol (2006) 1.46

Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus. J Virol (2003) 1.44

Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity (2003) 1.43

The immediate-early 63 protein of Varicella-Zoster virus: analysis of functional domains required for replication in vitro and for T-cell and skin tropism in the SCIDhu model in vivo. J Virol (2004) 1.40

Role of pediatric and internist rheumatologists in treating children with rheumatic diseases. Pediatrics (2004) 1.39

Mitochondrial cell death suppressors carried by human and murine cytomegalovirus confer resistance to proteasome inhibitor-induced apoptosis. J Virol (2005) 1.39

Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo. J Virol (2003) 1.38

The replication cycle of varicella-zoster virus: analysis of the kinetics of viral protein expression, genome synthesis, and virion assembly at the single-cell level. J Virol (2009) 1.38

The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells. Virology (2002) 1.37

Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. J Infect Dis (2010) 1.36

Microarray analysis of host cell gene transcription in response to varicella-zoster virus infection of human T cells and fibroblasts in vitro and SCIDhu skin xenografts in vivo. J Virol (2003) 1.33

Downregulation of class I major histocompatibility complex surface expression by varicella-zoster virus involves open reading frame 66 protein kinase-dependent and -independent mechanisms. J Virol (2007) 1.31

Betaherpesvirus-conserved cytomegalovirus tegument protein ppUL32 (pp150) controls cytoplasmic events during virion maturation. J Virol (2006) 1.30

Differentiation of varicella-zoster virus ORF47 protein kinase and IE62 protein binding domains and their contributions to replication in human skin xenografts in the SCID-hu mouse. J Virol (2003) 1.30

Glycoprotein I of varicella-zoster virus is required for viral replication in skin and T cells. J Virol (2002) 1.29

Viral and cell cycle-regulated kinases in cytomegalovirus-induced pseudomitosis and replication. PLoS Pathog (2007) 1.29

Varicella in the fetus and newborn. Semin Fetal Neonatal Med (2008) 1.29

Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J (2007) 1.28

Proapoptotic chemotherapeutic drugs induce noncanonical processing and release of IL-1β via caspase-8 in dendritic cells. J Immunol (2013) 1.28

Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin Immunol (2009) 1.27

HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism. Nat Struct Mol Biol (2012) 1.25

Promoter sequences of varicella-zoster virus glycoprotein I targeted by cellular transactivating factors Sp1 and USF determine virulence in skin and T cells in SCIDhu mice in vivo. J Virol (2003) 1.25

Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia. J Virol (2008) 1.23

Varicella-zoster virus productively infects mature dendritic cells and alters their immune function. J Virol (2003) 1.23

Viral gene expression during the establishment of human cytomegalovirus latent infection in myeloid progenitor cells. Blood (2006) 1.22

Productive varicella-zoster virus infection of cultured intact human ganglia. J Virol (2007) 1.22

Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol (2010) 1.20

Antiviral CD8 T cells in the control of primary human cytomegalovirus infection in early childhood. J Infect Dis (2004) 1.20

Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine (2003) 1.20

Viral modulation of programmed necrosis. Curr Opin Virol (2013) 1.20

Global analysis of host cell gene expression late during cytomegalovirus infection reveals extensive dysregulation of cell cycle gene expression and induction of Pseudomitosis independent of US28 function. J Virol (2004) 1.19

Analysis of the frequencies and of the memory T cell phenotypes of human CD8+ T cells specific for influenza A viruses. J Infect Dis (2003) 1.19

A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis (2006) 1.19

T-cell tropism and the role of ORF66 protein in pathogenesis of varicella-zoster virus infection. J Virol (2005) 1.19

Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation. Blood (2003) 1.19

Functions of the C-terminal domain of varicella-zoster virus glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo. J Virol (2004) 1.17

Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. Proc Natl Acad Sci U S A (2011) 1.16

Predicting coding potential from genome sequence: application to betaherpesviruses infecting rats and mice. J Virol (2005) 1.16

Differential requirement for cell fusion and virion formation in the pathogenesis of varicella-zoster virus infection in skin and T cells. J Virol (2004) 1.16

Cytomegalovirus MCK-2 controls mobilization and recruitment of myeloid progenitor cells to facilitate dissemination. Blood (2005) 1.15

Control of cytoplasmic maturation events by cytomegalovirus tegument protein pp150. J Virol (2008) 1.15

Viral and host control of cytomegalovirus maturation. Trends Microbiol (2012) 1.15

Functions of the ORF9-to-ORF12 gene cluster in varicella-zoster virus replication and in the pathogenesis of skin infection. J Virol (2008) 1.15

Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J Immunol (2002) 1.14

Disruption of PML nuclear bodies is mediated by ORF61 SUMO-interacting motifs and required for varicella-zoster virus pathogenesis in skin. PLoS Pathog (2011) 1.14

Functions of Varicella-zoster virus ORF23 capsid protein in viral replication and the pathogenesis of skin infection. J Virol (2008) 1.13

Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. J Infect Dis (2008) 1.12

Inhibition of the NF-kappaB pathway by varicella-zoster virus in vitro and in human epidermal cells in vivo. J Virol (2006) 1.12

Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. PLoS One (2008) 1.11

The role of the human cytomegalovirus UL111A gene in down-regulating CD4+ T-cell recognition of latently infected cells: implications for virus elimination during latency. Blood (2009) 1.11

Labeling antigen-specific CD4(+) T cells with class II MHC oligomers. J Immunol Methods (2002) 1.11

Plasticity of T-cell phenotype and function: the T helper type 17 example. Immunology (2009) 1.11

Oligoarticular and polyarticular JIA: epidemiology and pathogenesis. Nat Rev Rheumatol (2009) 1.11

Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation (2006) 1.11

Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus. PLoS Pathog (2011) 1.10

Varicella-zoster virus immediate-early protein 62 blocks interferon regulatory factor 3 (IRF3) phosphorylation at key serine residues: a novel mechanism of IRF3 inhibition among herpesviruses. J Virol (2010) 1.10

Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection. J Virol (2006) 1.10

RNA analysis by biosynthetic tagging using 4-thiouracil and uracil phosphoribosyltransferase. Methods Mol Biol (2008) 1.09

Human cytomegalovirus exploits ESCRT machinery in the process of virion maturation. J Virol (2009) 1.09

Selective developmental defects of cord blood antigen-presenting cell subsets. Hum Immunol (2004) 1.09

Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma (2006) 1.09